A Phase 2 interventional study of BFF MDI 320/9.6 μg and BFF MDI 160/9.6 μg in Chronic Obstructive Pulmonary Disease, sponsored by Pearl Therapeutics, Inc.. Completed at 17 sites in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-06-20.
Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive — 3 open to participants now, 3 under way, 1 of them phase 3. Budesonide · Pulmonary Disease, Chronic Obstructive.
Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, this one is the 15th largest by enrollment, is one of 4 that started in 2014, is one of 2 in phase 2, and was the 20th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →3 of the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
Maria Joyera Rodríguez · Sites in Germany, Netherlands, Spain and 1 more country
Ages 40+
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 99 across the 43 interventional studies. Of the 37 that completed or were terminated, 16 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 43 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pearl Therapeutics, Inc., one of the names counted as AstraZeneca. Under that name alone:
Pearl Therapeutics, Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 15 (94%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 85th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2014, is one of 54 in phase 2, and was the 155th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing budesonide in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies testing budesonide in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
This is a Phase IIb, randomized, double blind, chronic dosing (28 days), four period, five treatment, incomplete block, crossover design in subjects with moderate to severe COPD. The overall objective is to demonstrate that the combination of budesonide (BD; PT008) and formoterol fumarate (FF; PT005) in a metered-dose inhaler (MDI); (BFF MDI; PT009) provides benefit on lung function compared with BD MDI in subjects with moderate to severe COPD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Drug: BFF MDI 320/9.6 μg
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI)160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Drug: BFF MDI 160/9.6 μg
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Drug: BFF MDI 80/9.6 μg
Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
Drug: BD MDI 320 μg
Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
Drug: FF MDI 9.6 μg
Drug pages: Budesonide · Formoterol
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
FEV1 AUC0-12 on Day 29
Change from Baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 12 hours (AUC0-12)
Time frame: Day 29
Change From Baseline in Morning Pre-dose Trough FEV1 Over 28 Days
Time frame: Over 28 days
Peak Change From Baseline in FEV1 (in Liters) Day 15
Time frame: Day 15
Peak Change From Baseline in FEV1 (in Liters) Day 29
Time frame: Day 29
Peak Change From Baseline in FEV1 on Day 1
Time frame: Day 1
Forced Vital Capacity (FVC) AUC0-12 on Day 29
Time frame: Day 29
Transition Dyspnea Index (TDI) Focal Score on Day 29
Min/Max Range of TDI scale -9 (major deterioration) to +9 (major improvement)
Time frame: Day 29
Change From Baseline in Average Daily Use of Rescue Ventolin HFA Over the Last Week of Treatment
Time frame: Visit 12-13 (7 days)
This study was conducted at 20 sites in the United States from August 2014 to March 2015. Study participation was a maximum of 28 days.
| Milestone | Subjects |
|---|---|
| Started | 180 |
| Bff mdi 320/9.6 μg | 155 |
| Bff mdi 160/9.6 μg | 106 |
| Bff mdi 80/9.6 μg | 103 |
| Bd mdi 320 μg | 108 |
| Ff mdi 9.6 μg | 157 |
| Completed | 133 |
| Not completed | 47 |
| Withdrew: Adverse event | 4 |
| Withdrew: Lack of efficacy | 1 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Physician decision | 1 |
| Withdrew: Lost to follow-up | 3 |
| Withdrew: Protocol violation | 24 |
Change from Baseline in forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 12 hours (AUC0-12)
| Liters | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| FEV1 AUC0-12 on Day 29 | 0.231 (0.197 to 0.266) | 0.197 (0.158 to 0.236) | 0.205 (0.165 to 0.244) | 0.011 (-0.028 to 0.050) | 0.176 (0.141 to 0.210) |
| Liters | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 Over 28 Days | 0.138 (0.111 to 0.165) | 0.121 (0.089 to 0.153) | 0.110 (0.078 to 0.142) | 0.022 (-0.009 to 0.054) | 0.083 (0.056 to 0.110) |
| Liters | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| Peak Change From Baseline in FEV1 (in Liters) Day 15 | 0.388 (0.354 to 0.422) | 0.366 (0.327 to 0.405) | 0.348 (0.308 to 0.387) | 0.143 (0.104 to 0.182) | 0.320 (0.286 to 0.354) |
| Liters | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| Peak Change From Baseline in FEV1 (in Liters) Day 29 | 0.390 (0.356 to 0.424) | 0.356 (0.317 to 0.395) | 0.359 (0.319 to 0.398) | 0.138 (0.099 to 0.177) | 0.322 (0.287 to 0.356) |
| Liters | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| Peak Change From Baseline in FEV1 on Day 1 | 0.338 (0.304 to 0.372) | 0.310 (0.271 to 0.349) | 0.314 (0.275 to 0.354) | 0.096 (0.058 to 0.135) | 0.313 (0.279 to 0.347) |
| Liters | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| Forced Vital Capacity (FVC) AUC0-12 on Day 29 | 0.305 (0.244 to 0.365) | 0.245 (0.176 to 0.315) | 0.267 (0.196 to 0.337) | 0.002 (-0.068 to 0.071) | 0.253 (0.191 to 0.314) |
Min/Max Range of TDI scale -9 (major deterioration) to +9 (major improvement)
| Index | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| Transition Dyspnea Index (TDI) Focal Score on Day 29 | 0.598 (0.298 to 0.899) | 0.882 (0.518 to 1.246) | 0.459 (0.093 to 0.825) | -0.109 (-0.468 to 0.250) | 0.260 (-0.047 to 0.566) |
| Puffs | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| Change From Baseline in Average Daily Use of Rescue Ventolin HFA Over the Last Week of Treatment | 0.05 (-0.34 to 0.43) | 0.16 (-0.27 to 0.58) | 0.24 (-0.19 to 0.67) | 0.96 (0.54 to 1.38) | 0.44 (0.06 to 0.83) |
Collected over AEs were recorded from the time subjects received their first dose of study medication, during the entire study period, and up to 14 days from the date of the last study medication dose.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BFF MDI 320/9.6 ug | — | 4/155 (2.6%) | 12/155 (7.7%) |
| BFF MDI 160/9.6 ug | — | 2/106 (1.9%) | 2/106 (1.9%) |
| BFF MDI 80/9.6 ug | — | 3/103 (2.9%) | 5/103 (4.9%) |
| BD MDI 320 ug | — | 4/108 (3.7%) | 8/108 (7.4%) |
| FF MDI 9.6 ug | — | 2/157 (1.3%) | 8/157 (5.1%) |
| Event | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| Chronic Obstructive Pulmonary DiseaseRespiratory, thoracic and mediastinal disorders | 1/155 | 0/106 | 1/103 | 2/108 | 0/157 |
| Acute Myocardial InfarctionCardiac disorders | 0/155 | 0/106 | 1/103 | 0/108 | 0/157 |
| Angina PectorisCardiac disorders | 0/155 | 0/106 | 1/103 | 0/108 | 0/157 |
| Cerebrovascular AccidentNervous system disorders | 0/155 | 0/106 | 1/103 | 0/108 | 0/157 |
| Back PainMusculoskeletal and connective tissue disorders | 0/155 | 1/106 | 0/103 | 0/108 | 0/157 |
| Small Intestinal ObstructionGastrointestinal disorders | 0/155 | 1/106 | 0/103 | 0/108 | 0/157 |
| Clostridium Difficile ColitisInfections and infestations | 0/155 | 0/106 | 0/103 | 1/108 | 0/157 |
| Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/155 | 0/106 | 0/103 | 1/108 | 0/157 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/155 | 0/106 | 0/103 | 1/108 | 0/157 |
| Laryngeal OedemaRespiratory, thoracic and mediastinal disorders | 1/155 | 0/106 | 0/103 | 0/108 | 0/157 |
| Event | BFF MDI 320/9.6 ug | BFF MDI 160/9.6 ug | BFF MDI 80/9.6 ug | BD MDI 320 ug | FF MDI 9.6 ug |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/155 | 1/106 | 2/103 | 2/108 | 5/157 |
| HypertensionCardiac disorders | 2/155 | 1/106 | 1/103 | 3/108 | 2/157 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/155 | 0/106 | 1/103 | 3/108 | 1/157 |
| Upper Respiratory Tract InfectionInfections and infestations | 4/155 | 0/106 | 1/103 | 0/108 | 0/157 |
The ITT population used in participant flow, Population is defined as all subjects who were randomized to treatment and received at least one dose of BFF MDI 320/9.6 ug, BFF MDI 160/9.6 ug, BFF MDI 80/9.6 ug, BD MDI 320 ug or FF MDI 9.6 ug. Statistical tabulations and analyses will be by randomized treatment.
| Age, Continuous(Years) | Subjects |
|---|---|
| Mean | 62.2 ± 8.4 |
| Sex: Female, Male(Participants) | Subjects |
|---|---|
| Female | 96 |
| Male | 84 |
Plan to share: Yes
Ran from Aug 2014 to primary completion in Mar 2015, 7 months.
Results were first posted in May 2017, 2 years 2 months after primary completion. A results delay was requested in Feb 2016.
Of 118 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 7 months is below that.
Counting every sponsor, half of 165 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Budesonide · Formoterol
Pulmonary Disease, Chronic Obstructive →